Abstract:
INTRODUCTION:Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immune checkpoint inhibitors in advanced and metastatic gastric cancer, with a focus on pembrolizumab. Expert Commentary: Pembrolizumab has shown impressive activity in the third-line treatment of locally advanced and metastatic gastric cancer. It is currently being studied as upfront therapy in combination with chemotherapy. The emerging understanding of the molecular alterations and tumor immune microenvironment as predictors of immunotherapy response in gastric cancer are discussed. The impact of gastric mucosal dysbiosis on gastric carcinogenesis and the modulation of immunotherapy response by the gut microbiome are also reviewed.
journal_name
Expert Rev Anticancer Therjournal_title
Expert review of anticancer therapyauthors
Kamath SD,Kalyan A,Benson AB 3rddoi
10.1080/14737140.2018.1526084subject
Has Abstractpub_date
2018-12-01 00:00:00pages
1177-1187issue
12eissn
1473-7140issn
1744-8328journal_volume
18pub_type
杂志文章,评审abstract::Cancer cells generally maintain their survival by suppressing apoptosis. Mitochondrial mechanisms are involved in most forms of apoptosis (referred to as mitochondrial apoptosis), and the Bcl-2 family controls apoptosis at the mitochondrion via a balance of the effects of pro- and antiapoptotic members. Antiapoptotic ...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.4.6.1157
更新日期:2004-12-01 00:00:00
abstract::Bladder cancer is a significant cause of morbidity and mortality. Promising results with organ preservation strategies using multimodality treatment over the last decade offers an option for bladder preservation in a significant proportion of patients who currently undergo cystectomy. The primary goal of the bladder-s...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.2.6.641
更新日期:2002-12-01 00:00:00
abstract::This article reviews the current status of robotic-assisted radical prostatectomy (RARP) with outcome analysis. The published English literature (PubMed) database was searched extensively for major publications and large series on RARP. The search was carried out over the preceding 3-year period. Selected series were ...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.10.35
更新日期:2010-05-01 00:00:00
abstract::Epithelial ovarian cancer (EOC) remains a major source of cancer morbidity and mortality, despite advances in surgical and chemotherapeutic management. The molecular pathways that control angiogenesis have been demonstrated to be key to the pathogenesis of EOC, and have been shown to have prognostic significance. Incr...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.8.1.21
更新日期:2008-01-01 00:00:00
abstract::Interview by Sophia Maprayil and Alexandra Hemsley, Commissioning Editors Chris Twelves is a medical oncologist and leads the Section of Oncology and Clinical Research at Cancer Research UK's Clinical Centre at St James's Hospital, Leeds. His particular interest lies in new drug development and clinical pharmacology; ...
journal_title:Expert review of anticancer therapy
pub_type: 面试
doi:10.1586/era.13.3
更新日期:2013-03-01 00:00:00
abstract::Anemia is a common and potentially debilitating complication of cancer. Darbepoetin alfa (Aranesp, Amgen) has been in routine clinical use for the treatment of chemotherapy-induced anemia since 2002. The extended half-life of darbepoetin alfa permits less frequent and consequently more flexible dosing than other eryth...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.4.5.735
更新日期:2004-10-01 00:00:00
abstract::Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) represents a distinct disease entity whose molecular phenotype predicts exquisite sensitivity to the reversible EGFR-tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib. However, primary or acquired resistance to these agents remain...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1586/era.11.34
更新日期:2011-05-01 00:00:00
abstract:INTRODUCTION:The treatment landscape of metastatic prostate cancer has changed dramatically over the past five years. As new discoveries are made and further novel therapies become available, there is a heightened urgency to develop biomarkers that can guide prognoses and predict therapy responses. Circulating tumor ce...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1080/14737140.2017.1359544
更新日期:2017-10-01 00:00:00
abstract::The treatment of metastatic colorectal cancer has evolved greatly in the last 15 years, involving combined chemotherapy protocols and, in more recent times, new biologic agents. Clinical benefit from the use of targeted therapy with bevacizumab, aflibercept, cetuximab, panitumumab and regorafenib in the treatment of m...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.2014.949678
更新日期:2014-12-01 00:00:00
abstract::Breast cancer (BC) comprises a group of different diseases characterized by changes in tissue structure and gene expression. Recent advances in molecular biology have shed new light on the participation of genes and their products in the biology of BC. MicroRNAs (miRNAs) are small noncoding endogenous RNA molecules th...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.11.40
更新日期:2011-08-01 00:00:00
abstract::Although the general intent of treatment for patients with recurrent ovarian cancer is palliative, and cure does not seem to be a realistic objective in this setting, median overall survival is greater than 12 months in platinum-sensitive recurrent ovarian cancer. Patients with ovarian cancer can now expect that the t...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.6.3.437
更新日期:2006-03-01 00:00:00
abstract::Introduction: Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and the third largest cause of cancer-relateddeaths worldwide. Potentially curative treatments (surgical resection, radiofrequency or liver transplantation) are only available for few patients, while transarterial chemoembolizat...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章
doi:10.1080/14737140.2020.1712198
更新日期:2020-01-01 00:00:00
abstract::Dietary factors and other naturally occurring substances may emerge as potent therapeutic or preventative agents in the battle against prostate cancer. Much of the current support for these agents is epidemiologically based, but new prospective studies are now underway which may support their use in conventional medic...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.3.2.203
更新日期:2003-04-01 00:00:00
abstract::Current targeted strategies for cancer focus on the blockade of growth factor receptors and the inhibition of angiogenesis. The VEGF pathway has become an attractive target in multiple malignancies, including lung cancer. Bevacizumab, a monoclonal antibody against VEGF, increased survival in non-small-cell lung cancer...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.11.80
更新日期:2011-08-01 00:00:00
abstract::Androgen deprivation therapy is the standard of care for the initial treatment of metastatic prostate cancer. However, the majority of these patients live long enough to experience disease progression despite castration. This scenario is defined as castration-resistant prostate cancer (CRPC) and has a poor outcome and...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.2013.811154
更新日期:2013-07-01 00:00:00
abstract::While early-stage endometrial cancer is highly curable after hysterectomy for the majority of patients afflicted with this disease, recurrent and metastatic endometrial cancer continues to pose a significant challenge. The median survival of women with advanced or recurrent uterine cancer on most recent clinical trial...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.09.54
更新日期:2009-07-01 00:00:00
abstract::Sophia Maprayil, Commissioning Editor for Expert Review of Anticancer Therapy, talks to Dr Iain Frame, Director of Research for Prostate Cancer UK. Iain is Prostate Cancer UK's first Director of Research, responsible for overseeing the development and implementation of the charity's ambitious new research strategy. He...
journal_title:Expert review of anticancer therapy
pub_type: 面试
doi:10.1586/14737140.2014.974898
更新日期:2014-11-01 00:00:00
abstract::The desmoid tumors (DTs) are unusual soft-tissue tumors that have a propensity for aggressive local growth and may develop during, or soon after pregnancy. Pregnancy-associated DTs are uncommon and optimal management of this tumor has yet to be defined. Currently, controversy centers on the timing of surgical resectio...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.09.98
更新日期:2009-11-01 00:00:00
abstract::Treatment options for patients have increased over the last few years, especially with the availability of novel agents for routine care and within clinical trials. Owing to the promising activity seen with lenalidomide in the relapsed/refractory setting, its use has now expanded to induction and maintenance therapy. ...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.09.123
更新日期:2009-11-01 00:00:00
abstract::Stereotactic body radiation therapy (SBRT) involves delivery of image-guided, ablative radiation doses to planning treatment volume(s) using sophisticated dosimetric planning and target localization. Early on, clinical investigators pursued SBRT for the treatment of early stage non-small-cell lung cancer, lung and liv...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.11.81
更新日期:2011-07-01 00:00:00
abstract::Accelerated partial breast irradiation has been investigated in selected patients with early-stage breast cancer. Accelerated partial breast irradiation limits the radiation target to the volume of tissue immediately surrounding the lumpectomy cavity and reduces the overall treatment time from approximately 6 weeks to...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.11.113
更新日期:2011-09-01 00:00:00
abstract::Rapid malignant proliferation, prior to effective tumor neoangiogenesis, creates a microenvironment around solid cancers, which is predominantly hypoxic and characterized by a high interstitial fluid pressure. Presumably as an adaptive response, tumor cells favor metabolic activity with apparently inefficient energy o...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.2013.843455
更新日期:2013-10-01 00:00:00
abstract::Although testicular cancer is currently a rare disease, the incidence is rising. The most important risk factor remains cryptorchism and there is a variable association with testicular microlithiasis. Serum tumor markers remain important for diagnosis, and they have prognostic value and can be used to monitor therapy ...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.4.4.669
更新日期:2004-08-01 00:00:00
abstract:INTRODUCTION:Mesothelioma is a rare type of cancer that is strongly tied to asbestos exposure. Despite application of different modalities such as chemotherapy, radiotherapy and surgery, patient prognosis remains very poor and therapies are ineffective. Much research currently focuses on the application of novel approa...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1080/14737140.2017.1358091
更新日期:2017-09-01 00:00:00
abstract::Introduction: CDK4/6 inhibitor approval for hormone-responsive breast tumors has significantly changed therapeutic algorithms, with three drugs currently approved. Areas covered: Here, we analyze the toxicity profiles of palbociclib, ribociclib, and abemaciclib through a systematic review and meta-analysis. Palbocicli...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章
doi:10.1080/14737140.2021.1852934
更新日期:2020-12-13 00:00:00
abstract::Advanced transitional-cell carcinoma of the bladder is the most common cancer of the urinary tract, with a high mortality rate. Cisplatin-based chemotherapy has demonstrated prolonged survival of these patients and is considered the standard of care. Nevertheless, 40-50% of patients have impaired renal function that p...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.10.197
更新日期:2011-06-01 00:00:00
abstract::Giant cell tumor of bone is a locally aggressive lesion with a predilection for local recurrence, and in a small proportion of patients, metastatic disease can develop. Surgery is the mainstay of management for extremity-based lesions. For tumors located in challenging anatomical locations such as the sacrum and spine...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.2014.901891
更新日期:2014-07-01 00:00:00
abstract::Waldenström's macroglobulinemia is a distinct disorder characterized by a monoclonal immunoglobulin M paraprotein and morphological evidence of lymphoplasmacytic lymphoma. It is relatively rare, accounting for approximately 2% of all hematological malignancies. The aim of treatment for patients with Waldenström's macr...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.6.3.329
更新日期:2006-03-01 00:00:00
abstract::A lymphocele is a cystic mass that may occur in the retroperitoneum following a systematic pelvic and/or para-aortic lymphadenectomy. Lymphoceles may be the cause of severe morbidity, or rarely mortality. Symptomatic lymphoceles manifest with pain, compression of adjacent structures, lymphoedema, deep vein thrombosis ...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.2014.866043
更新日期:2014-03-01 00:00:00
abstract::The purpose of this article is to outline the current approach to patients affected by metastasis to the long bones and to present a clinical and surgical algorithm available for clinicians and for future research. A modern approach to patients affected by long bone metastasis in fact requires a multidisciplinary cont...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章
doi:10.1586/14737140.2014.947691
更新日期:2014-10-01 00:00:00